



**Annual Utilization of Biologic Response Modifiers Among Continually Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2006**



\* Small cell = less than 11.


**Annual Utilization of Biologic Response Modifiers Among Continually Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2007**



\* Small cell = less than 11.




**Annual Utilization of Biologic Response Modifiers Among Continually Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2008**



\* Small cell = less than 11.


**Annual Utilization of Biologic Response Modifiers Among Continually Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009**



\* Small cell = less than 11.




**Annual Utilization of Kinase Inhibitors Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2006**



\* Small cell = less than 11.


**Annual Utilization of Kinase Inhibitors Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2007**



\* Small cell = less than 11.




**Annual Utilization of Kinase Inhibitors Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2008**



\* Small cell = less than 11.


**Annual Utilization of Kinase Inhibitors Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009**



\* Small cell = less than 11.




**Annual Utilization of Miscellaneous Biologic Nonblood Products Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2006**



\* Small cell = less than 11.


**Annual Utilization of Miscellaneous Biologic Nonblood Products Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2007**



\* Small cell = less than 11.




**Annual Utilization of Miscellaneous Biologic Nonblood Products Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2008**



\* Small cell = less than 11.


**Annual Utilization of Miscellaneous Biologic Nonblood Products Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009**



\* Small cell = less than 11.




**Annual Utilization of Monoclonal Antibodies Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2006**



\* Small cell = less than 11.


**Annual Utilization of Monoclonal Antibodies Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2007**



\* Small cell = less than 11.




**Annual Utilization of Monoclonal Antibodies Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2008**



\* Small cell = less than 11.


**Annual Utilization of Monoclonal Antibodies Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009**



\* Small cell = less than 11.




**Annual Utilization of Other Immunomodulators Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2006**



\* Small cell = less than 11.


**Annual Utilization of Other Immunomodulators Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2007**



\* Small cell = less than 11.




**Annual Utilization of Other Immunomodulators Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2008**



\* Small cell = less than 11.


**Annual Utilization of Other Immunomodulators Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009**



\* Small cell = less than 11.




**Annual Utilization of Other Immunosuppressives Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2006**



\* Small cell = less than 11.


**Annual Utilization of Other Immunosuppressives Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2007**



\* Small cell = less than 11.




**Annual Utilization of Other Immunosuppressives Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2008**



\* Small cell = less than 11.


**Annual Utilization of Other Immunosuppressives Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009**



\* Small cell = less than 11.




**Annual Utilization of BCG Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009**



\* Small cell = less than 11.  
BCG = Bacillus Calmette-Guerin.


**Annual Utilization of Bevacizumab Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009**



\* Small cell = less than 11.




**Annual Utilization of Bortezomib Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009**



\* Small cell = less than 11.


**Annual Utilization of Cyclosporine Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009**



\* Small cell = less than 11.




**Annual Utilization of Imatinib Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009**



\* Small cell = less than 11.


**Annual Utilization of Rituximab Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009**



\* Small cell = less than 11.



**Annual Utilization of Trastuzumab Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009**



\* Small cell = less than 11.